Lumicell
Lumicell develops fluorescence imaging technology for cancer surgery. Its FDA-approved LumiSystem helps surgeons find residual cancer in real-time.
Secondary Market Price
How Lumicell Measures Up
To help you manage your Lumicell equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series F
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Lumicell's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Lumicell Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Lumicell's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Lumicell is a company developing and commercializing fluorescence imaging technology designed to help surgeons identify residual cancer in real-time during surgery. The company's current focus is on breast cancer lumpectomy procedures, having recently received FDA approval for its LUMISIGHT™ (pegulicianine) imaging agent and the Lumicell™ DVS imaging device. Following these approvals, the company initiated the U.S. launch of its LumiSystem™ for the intraoperative detection of remaining breast cancer. The company's history is rooted in clinical development, involving extensive trials and collaborations with investigators and patients that led to its current commercial-stage status.
Lumicell is also exploring the application of its technology for other types of cancer, including gastrointestinal and esophageal cancers, and has reported promising findings from a feasibility trial in gastrointestinal cancer patients. The company was awarded a Phase I NIH SBIR contract to develop a flexible endoscope for detecting early esophageal lesions in patients with Barrett’s Esophagus. Other recent announcements include the first commercial use of the LumiSystem™ in January 2025 and a September 2024 decision by CMS to grant transitional pass-through payment for LUMISIGHT™ to increase patient access.
- BlueIO
- LaunchCapital
- Kodiak Venture Partners
- Index Ventures
- National Cancer Institute
- Rivas Capital LLC
- Quantum Valley Investments
- Co-Founder, W. David Lee
- Co-Founder, Moungi G. Bawendi
- Co-Founder, Andrey Zarur
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Lumicell worth joining?
Deciding whether to join any private company involves carefully evaluating your compensation package, particularly the equity component. Platforms like Prospect can help you model the potential future value of your stock options or RSUs to make a more informed decision.
What should I do with my Lumicell stock?
The right strategy for your private company stock depends on your personal financial situation, risk tolerance, and tax implications. You can use a service like Prospect to get customized strategies for exercising options, planning for taxes, and deciding when to sell.
Can you sell Lumicell stock?
As a private company, Lumicell stock is not publicly traded, but selling may be possible during specific events like a tender offer or on a secondary market. Tools from platforms such as Prospect can help you determine how much to sell and which shares are most tax-optimal during these liquidity events.
How can I find the value of my Lumicell stock?
Since Lumicell is a private company, its stock value isn't listed on a public exchange and is determined by internal 409A valuations and market interest. To get a better sense of its potential, Prospect offers predictive models that forecast the future value of private company shares.
What is Lumicell's equity worth?
The precise worth of private equity fluctuates and is not publicly available until an IPO or acquisition. You can use equity management platforms to project your stock's potential future value and model different financial scenarios.
What is Lumicell's stock ticker symbol?
Lumicell does not have a stock ticker symbol because it is a private company. Ticker symbols are only assigned to companies when they become publicly traded on a stock exchange.
Can I buy or sell Lumicell stock?
Buying or selling stock in a private company like Lumicell is restricted and typically only happens during specific liquidity events, such as a tender offer. While some platforms do not facilitate transactions, they provide tools to help existing shareholders optimize their selling strategy for when such opportunities arise.
What is the criteria to buy or invest in Lumicell stock?
Investing in a private company is generally restricted to accredited investors or employees who receive equity as part of their compensation. Equity management platforms are typically designed for these existing shareholders to manage their holdings, rather than for new investors to buy in.
